Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06377930 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy
A Phase 2 study of Focal Onset Seizures, sponsored by Rapport Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 12
- Study locations
NCT06377930: Completed Phase 2 study of Focal Onset Seizures, sponsored by Rapport Therapeutics.
NCT06377930 is a Phase 2 study of Focal Onset Seizures that has completed, run by Rapport Therapeutics. The registered enrollment target is 30 participants, below the 275-participant average among 4 other Focal Onset Seizures trials with a reported enrollment target (89% lower). The trial reports 12 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06377930, a Phase 2 study of Focal Onset Seizures, has completed, sponsored by Rapport Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with Refractory Focal Epilepsy.
Primary Outcome
Change in long episode frequency per 28-day period during the treatment period compared to baseline
Conditions Studied
Interventions
- DRUG RAP-219
Study Locations (12)
Pennsylvania
- University of Pennsylvania - Department of Neurology - Philadelphia
- Thomas Jefferson University - Philadelphia
Texas
- Baylor College of Medicine - Houston
- University of Texas Health Science Center, Houston - Houston
Connecticut
- Yale University - New Haven
Idaho
- Consultants in Epilepsy and Neurology, PLLC - Boise
Indiana
- IU Health Neuroscience Center, Goodman Hall - Indianapolis
Kansas
- The University of Kansas Medical Center Epilepsy Clinic - Kansas City
Minnesota
- Mayo Clinic - Rochester
New York
- NYU Langone Comprehensive Epilepsy Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-10-10 |
| Est. Completion | 2025-09-26 |
| Phase | Phase 2 |
What the finished NCT06377930 record still lists
NCT06377930 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 275-participant average among 4 other Focal Onset Seizures trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Focal Onset Seizures appearing as the primary indexed condition, and to 1 intervention - of which RAP-219 is the first listed.
NCT06377930 lists 12 locations in 10 states (Pennsylvania, Texas, Connecticut).
Frequently Asked Questions
What is clinical trial NCT06377930 about?
NCT06377930 is a clinical study titled "Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy". This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with Refractory Focal Epilepsy.
What is the current status of trial NCT06377930?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2024-10-10. Estimated completion is 2025-09-26.
What conditions does trial NCT06377930 study?
This clinical trial studies the following conditions: Focal Onset Seizures.
What interventions are being tested in trial NCT06377930?
The interventions under investigation include: RAP-219 (DRUG).
Who is sponsoring clinical trial NCT06377930?
This trial is sponsored by Rapport Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06377930 being conducted?
This trial has 12 study locations across Connecticut, Idaho, Indiana, Kansas, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Focal Onset Seizures
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures
RECRUITING · Phase 2
-
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures
RECRUITING · Phase 2
-
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
RECRUITING · Phase 3
-
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI